Venture capital investing across life science sector

Co-Founded and funded by Tiger Management L.L.C., Tiger Gene invests in technology-stage assets with disruptive, high-growth trajectories and robust IP estates

Company Formation and Investment Across the
Life Science Contiuum

Founded by Tiger Management L.L.C. and John Boyce, Tiger Gene forms and invests in platform technology companies that are able to produce assets with disruptive, high-growth trajectories and robust IP estates

Home

Portfolio

Enabling Spatial Protein Assembly with Engineered mRNA and tRNA for Novel Protein Therapeutics: Precise Protein Origami™

With technology exclusively licensed from Dr. Abhishek Chatterjee's laboratory at Boston College, BrickBio (co-founded by Dr. Chatterjee of Boston College and John Boyce, Tiger Gene) enables next-generation site-specific protein modification via the incorporation of unnatural amino acids. BrickBio's platform technology generates novel classes of biologics, including multi-site bispecific antibodies and protein therapeutics with enhanced characteristics, such as half-life, dosage and efficacy.

End User Customizable Proteomics (DIY ) with Broad Dynamic Range, Digital Readouts, with Multi-Omics Analysis

With technology exclusively licensed from Dr. Qimin Quan's laboratory at Harvard University, NanoMosaic (co-founded by Dr. Quan of Harvard University and John Boyce, Tiger Gene) leverages the power of nanoneedles for protein detection and quantification to develop best-in-class assays for biomarker discovery and validation. The NanoMosaic platform, Tessie, enables users to customize their own content on chips, obtain greater than seven orders of dynamic range detection, while maintaining high sensitivity, high multiplexing, and label-free assays at low cost.

Reprogrammed and Engineered AAVs for Gene Therapy

EnCapsid is able to erase the tropism of an AAV and reprogram that AAV to a specific target, and only that target tissue. The company has shown that the reprogrammed AAV’s tropism is conserved in vivo and that the reprogrammed AAV does not induce an immunogenic response. The company is also able to engineer novel AAVs, i.e. with greater packing densities to accommodate CRISPR/Cas9. The technology is based on methodologies invented by Dr. Abhishek Chatterjee at Boston College and the company was founded by Dr. Chatterjee, Audrey Warner of Tiger Gene, and John Boyce of Tiger Gene.